Stany Zjednoczone - angielski - NLM (National Library of Medicine)

nexus pharmaceuticals llc - fluorescein (unii: tpy09g7xir) (fluorescein - unii:tpy09g7xir) - fluoresecin injection 10%, , (100 mg/ml) and fluorescein injection 25% (250 mg/ml) is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. fluorescein injection, usp is contraindicated in patients with known hypersensitivity to fluorescein sodium or any other ingredients in this product. rare cases of death due to anaphylaxis have been reported [see warnings and precautions (5.1) and adverse reactions (6.2)] . pregnancy category c. adequate animal reproduction studies have not been conducted with fluorescein sodium. it is also not known whether fluorescein sodium can cause fetal harm when administered to a pregnant woman. fluorescein sodium should be given to a pregnant woman only if clearly needed. fluorescein sodium has been demonstrated to be excreted in human milk. caution should be exercised when fluorescein sodium is administered to a nursing woman. pediatric patients have been included in clinical studies. no overall differences in safety or effectiveness ha

Australia - angielski - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - fluorescein sodium, quantity: 113.2 mg/ml (equivalent: fluorescein, qty 100 mg/ml) - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - indications as at 01 jan 1991 : indicated in diagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - fluorescein sodium, quantity: 100 mg/ml - injection - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - diagnostic: intravenous injection of sodium fluorescein dye followed by multiframe photography (angiography) or opthalmoscopic evaluation (angioscopy). used in evaluation of wide range of retinal and choroidal diseases. less commonly used to evaluate abnormalities of the optic nerve and iris. may be used in the diagnosis and management of macular and vascular (including diabetic) diseases.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir) - ak-fluor® 10% (100 mg/ml) and 25% (250 mg/ml) is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. 4.1 hypersensitivity ak-fluor® is contraindicated in patients with known hypersensitivity to fluorescein sodium or any other ingredients in this product. rare cases of death due to anaphylaxis have been reported [see warnings and precautions (5.1) and adverse reactions (6.2)]. 8.1 pregnancy pregnancy category c. adequate animal reproduction studies have not been conducted with fluorescein sodium. it is also not known whether fluorescein sodium can cause fetal harm when administered to a pregnant woman. fluorescein sodium should be given to a pregnant woman only if clearly needed. 8.3 nursing mothers fluorescein sodium has been demonstrated to be excreted in human milk. caution should be exercised when fluorescein sodium is administered to a nursing woman. 8.4 pediatric use pediatric patients have been included in clinical studies. no overall differences in sa

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

akorn - fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir) - fluorescein sodium 100 mg in 1 ml - ak-fluor® 10% (100 mg/ml) and 25% (250 mg/ml) is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. ak-fluor® is contraindicated in patients with known hypersensitivity to fluorescein sodium or any other ingredients in this product. rare cases of death due to anaphylaxis have been reported [see warnings and precautions (5.1) and adverse reactions (6.2) ]. pregnancy category c. adequate animal reproduction studies have not been conducted with fluorescein sodium. it is also not known whether fluorescein sodium can cause fetal harm when administered to a pregnant woman. fluorescein sodium should be given to a pregnant woman only if clearly needed. fluorescein sodium has been demonstrated to be excreted in human milk. caution should be exercised when fluorescein sodium is administered to a nursing woman. pediatric patients have been included in clinical studies. no overall differences in safety or effectiveness have been observed between pediatric and adult patient

Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

serb - fluorescein sodium - solution for injection - 88.3mg/1ml

Australia - angielski - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - fluorescein sodium, quantity: 250 mg/ml - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - indications as at 01 january 1991 : diagnostic - intravenous injection of sodium fluorescein dye followed by multiframe photography (angiography) or ophthalmoscopic evaluation (angioscopy). used in evaluation of wide range of retinal and choroidal diseases. less commonly used to evaluate abnormalities of the optic nerve and iris. may be used in diagnosis and management of macular and vascular (including diabetes) diseases.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - fluorescein sodium, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - indications as at 01 january 1991 : diagnostic - intravenous injection of sodium fluorescein dye followed by multiframe photography (angiography) or ophthalmoscopic evaluation (angioscopy). used in evaluation of wide range of retinal and choroidal diseases. less commonly used to evaluate abnormalities of the optic nerve and iris. may be used in diagnosis and management of macular and vascular (including diabetes) diseases.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

bausch & lomb (nz) ltd - fluorescein sodium 0.25%{relative};  ; lidocaine hydrochloride monohydrate 4%{relative};   - eye drops, solution - active: fluorescein sodium 0.25%{relative}   lidocaine hydrochloride monohydrate 4%{relative}   excipient: hydrochloric acid povidone water for injection

Kanada - angielski - Health Canada

pharma stulln inc. - fluorescein sodium - solution - 250mg - fluorescein sodium 250mg - other diagnostic agents